Evidence map›Paper›PMID 35280671›Full record

ArticleInternational journal of biological sciences2022

Pantothenate Kinase 1 Inhibits the Progression of Hepatocellular Carcinoma by Negatively Regulating Wnt/β-catenin Signaling.

Yuyuan Zi, Jie Gao, Chenglv Wang, Yidi Guan, Linzhao Li, Xinxin Ren, Lan Zhu, Yun Mu, Shuang-Hui Chen, Zimei Zeng and 12 more

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Astragalus Polysaccharides Target the Wnt/β-catenin Pathway to Suppress Malignant Behavior in Hepatocellular Carcinoma.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Translational cancer research · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 1 country.

Yuyuan ZiDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Jie GaoDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Chenglv WangNHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Yidi GuanDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Linzhao LiNHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Xinxin RenDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Lan ZhuNHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Yun MuDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Shuang-Hui ChenNHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Zimei ZengDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhen CaoDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhuoxian RongDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Pan ChenHunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Xiuping ZhangFaculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA), General Hospital, Beijing, China.
Tao ChenState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China.
Haiguang XinDepartment of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Xuebing LiTianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, P. R. China.
Zhi LiDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Lunquan SunDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Yuezhen DengDepartment of Oncology, Xiangya Cancer Center, Xiangya Hospital, Central South University, Changsha 410008, China.
Nan LiDepartment of Hepatic Surgery I (Ward I), Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China.
Yingjie NieNHC Key Laboratory of Pulmonary Immune-related Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China.
Xiangya Hospital Central South University · CNGuizhou Provincial People's Hospital · CNCentral South University · CNEastern Hepatobiliary Surgery Hospital · CNSecond Military Medical University · CNHunan Cancer Hospital · CNRuijin Hospital · CNState Key Laboratory of Respiratory Disease · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperactivation of Wnt/β-catenin signaling has been reported in hepatocellular carcinoma (HCC). However, the mechanisms underlying the hyperactivation of Wnt/β-catenin signaling are incompletely understood. In this study, Pantothenate kinase 1 (PANK1) is shown to be a negative regulator of Wnt/β-catenin signaling. Downregulation of PANK1 in HCC correlates with clinical features. Knockdown of PANK1 promotes the proliferation, growth and invasion of HCC cells, while overexpression of PANK1 inhibits the proliferation, growth, invasion and tumorigenicity of HCC cells. Mechanistically, PANK1 binds to CK1α, exerts protein kinase activity and cooperates with CK1α to phosphorylate N-terminal serine and threonine residues in β-catenin both in vitro and in vivo. Additionally, the expression levels of PANK1 and β-catenin can be used to predict the prognosis of HCC. Collectively, the results of this study highlight the crucial roles of PANK1 protein kinase activity in inhibiting Wnt/β-catenin signaling, suggesting that PANK1 is a potential therapeutic target for HCC.

Indexed as

Carcinoma, HepatocellularLiver Neoplasmsbeta CateninCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessPhosphotransferases (Alcohol Group Acceptor)Protein KinasesWnt Signaling Pathwaybeta Cateninpantothenate kinasePhosphotransferases (Alcohol Group Acceptor)Protein KinasesCK1αhepatocellular carcinomaPANK1protein kinase activityWnt/β-catenin signaling

Identifiers

PMID35280671
PMCPMC8898371
OpenAlexW4210530972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.